Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290079 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03290079 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT03290079, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to: * Assess overall radiographic response rate (ORR) * Assess progression-free survival (PFS) * Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2024-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03290079
The ClinicalTrials.gov registry entry for NCT03290079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03290079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03290079 about?
NCT03290079 is a clinical study titled "Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors". The purpose of this study is to: * Assess overall radiographic response rate (ORR) * Assess progression-free survival (PFS) * Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
What is the current status of trial NCT03290079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-12-15. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT03290079?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT03290079?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.